News Releases

  • 02 Feb 2016

    Industry Veteran, Steve Lam, to Direct Rapidly Expanding Business

    DURHAM, N.C.--(BUSINESS WIRE)--Patheon today announced the appointment of Steve Lam as senior vice president of the company’s biologics business. Lam will report to Lukas Utiger, president of the company’s Drug Substance Services (DSS) segment, effective immediately. Biologics is a fast-growing area of the industry, which requires experience and expertise because of their complexity. For the past 18 years, Lam has served as vice president of operations for Amgen, onemore...
  • 11 Jan 2016

    Gilles Cottier to lead the company’s PDS business

    DURHAM, N.C.--(BUSINESS WIRE)--Patheon announced today the appointment of Gilles Cottier as president of the company’s pharmaceutical development services (PDS) division effective immediately. He will serve as a member of Patheon’s executive committee and will report to Patheon CEO James Mullen. The appointment of Cottier is part of a larger realignment effort by the company to create three distinct business segments – drug product services (DPS), drug substance services (more...
  • 22 Oct 2015

    Company to present 17 posters on a range of topics from validation of stability to process optimization

    Experts from Patheon, a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma industries, will present on a breadth of industry topics at the 2015 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition, being held Oct. 25-29 in Orlando, Fla.Marshall Crew, vice president of global PDS scientific excellence, will deliver a presentation titled, “Improving Poor Solubility and Bioavailability with Solidmore...